RSV Patient Network is involved in:
Preparing for RSV immunisation and surveillance in Europe
Other interesting RSV studies:
Preparing for RSV immunisation and surveillance in Europe
ComNet III study
The ComNet III study aims to determine the burden of RSV infection in young children in primary care.
The RAPID study aims to determine the burden of RSV-infection in older adults in primary care.
PROMISE case-control study
The aim of the PROMISE case-control study is to find out why some children with RSV-infection become more ill than others.
The ReSViNET Foundation and ReSViNET’s Patient Network are partners in IMI’s PROMISE study. The aim of PROMISE is to significantly advance our understanding of RSV to aid in the design of public health strategies as well as the development and use of vaccines and therapeutics in both children and older people. It builds on the work of IMI’s RESCEU project, which has delivered significant insights and resources on RSV.
PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) brings together translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies from 22 world class organisations to make a breakthrough in RSV (Respiratory Syncytial Virus) research. Specifically, this initiative funded by the Innovative Medicines Initiative (IMI), focuses on advancing scientific knowledge on RSV to inform public health strategies and bolster the development and introduction of novel immunisations tools and therapeutics in Europe. Since the development of preventative measures such as a vaccine and monoclonal antibodies are well under way, PROMISE aims to prepare for the introduction of such treatments and prophylactic interventions.
PROMISE is located in:
As a Foundation, we aim to combat RSV (Respiratory Syncytial Virus) all around the world. Therefore, it is important for us to create more awareness of the disease that is caused by RSV. We have joined forces with Sanofi to set-up a survey study, to learn what parents need from organisations and health practitioners to be well informed about RSV. Moreover, we wanted to gain a better understanding of your opinion as a (soon to be) parent on vaccinating your child against RSV and what method of vaccinating you prefer. The study has been completed.
PROMISE case-control Study
The aim of the PROMISE case control study is to find out why some children with RSV-infection become more ill than others. For this reason, we look at certain biomarkers (proteins) in the body that might tell us something about the severity of disease. We collect blood, saliva, urine and faeces of previously healthy term born babies under the age of one. Hereby, we aim to gain more insight into the differences in biomarkers of children with severe RSV-infection, compared to children with less severe RSV-infection and healthy children. In the future, we hope this information enables us to determine which children are at high risk for severe infection with this virus. This PROMISE study is conducted in a European collaboration of academic hospitals and pharmaceutical companies, called the PROMISE consortium. Currently, only children in the Netherlands are included in the PROMISE case-control study.
‘’The PRIMA birth cohort aims to study which components in breastfeeding contribute to its protection of the infant against the development of respiratory tract infections and allergies in their first year of life. For this, we intend to follow 1000 healthy mother-child pears in Utrecht and surroundings, in the centre of the Netherlands. Along the way, several sub-studies and projects have been implemented within the cohort. We are also looking into the antibody-transfer via the placenta, amniotic fluid and breast milk in 5-15 mother-child pairs. Currently, a sub-study of 250 mother-child pairs is ongoing in which we additionally ask the mothers to fill in questionnaires about their diet. With this information, we can study the impact of the maternal diet on the breast milk composition and with that, on the protection the breast milk provides. For more information, please take a look at the website (Dutch only) or contact us via firstname.lastname@example.org.’
COMNET III Study
The ComNet III study aims to determine the burden of RSV infection in young children in primary care. Although there has been extensive research into the burden of severe RSV disease, much less is known on the burden of RSV disease of children that only visit the general practitioner, and are not hospitalised. New RSV medicines, vaccines and preventative options are under development and expected on the market soon. Therefore, more insight into the burden of RSV disease in primary care is essential for policymakers to decide whether a potential vaccine should become available to all children via a national immunisation programme.
Children with respiratory symptoms will be tested for RSV by their general practitioner. If RSV positive, parents will be asked to participate. The study consists of three questionnaires at day 1, 14 and 30 of RSV-infection, with questions regarding health care use for the RSV infection, clinical symptoms and health status of the child, but also its impact on the family. The study is conducted in Spain, Italy, The Netherlands, Belgium and the United Kingdom. The aim is to include at least 100 children with RSV infection per country.
* In The Netherlands this study is called the BIRD study
The RAPID study aims to determine the burden of RSV-infection in elderly in primary care. Similar to young children, the majority of RSV-infections in elderly do not require hospitalisation, and are managed outside the hospital. With an RSV vaccine for elderly expected soon, more information on the burden of RSV infection in primary care is needed for policymakers to decide on the implementation of an RSV vaccine for all elderly.
Adults that are 60 years or older and visit their general practitioner with respiratory symptoms will be tested for RSV by a nasal swab. In case of an RSV infection, they will be asked to complete a total of three questionnaires, at day 0, 14 and 30 of infection. The questions focus on health status, medicine use and impact on the ability to carry out usual daily and social activities. The RAPID study is conducted in The Netherlands. In total, 150 older adults will be included.